nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—lung cancer	0.311	1	CbGaD
Linagliptin—ABCB1—Topotecan—lung cancer	0.0447	0.0864	CbGbCtD
Linagliptin—ABCB1—Gefitinib—lung cancer	0.0409	0.079	CbGbCtD
Linagliptin—ABCB1—Vinorelbine—lung cancer	0.0315	0.0609	CbGbCtD
Linagliptin—CYP3A4—Topotecan—lung cancer	0.0268	0.0518	CbGbCtD
Linagliptin—ABCB1—Crizotinib—lung cancer	0.0251	0.0484	CbGbCtD
Linagliptin—CYP3A4—Gefitinib—lung cancer	0.0245	0.0473	CbGbCtD
Linagliptin—ABCB1—Gemcitabine—lung cancer	0.0245	0.0473	CbGbCtD
Linagliptin—ABCB1—Erlotinib—lung cancer	0.0242	0.0467	CbGbCtD
Linagliptin—CYP3A4—Teniposide—lung cancer	0.0238	0.0459	CbGbCtD
Linagliptin—ABCB1—Paclitaxel—lung cancer	0.0221	0.0428	CbGbCtD
Linagliptin—ABCB1—Irinotecan—lung cancer	0.0218	0.0422	CbGbCtD
Linagliptin—ABCB1—Vinblastine—lung cancer	0.0194	0.0375	CbGbCtD
Linagliptin—CYP3A4—Vinorelbine—lung cancer	0.0189	0.0365	CbGbCtD
Linagliptin—ABCB1—Cisplatin—lung cancer	0.0178	0.0344	CbGbCtD
Linagliptin—ABCB1—Etoposide—lung cancer	0.0175	0.0338	CbGbCtD
Linagliptin—ABCB1—Docetaxel—lung cancer	0.016	0.0309	CbGbCtD
Linagliptin—CYP3A4—Crizotinib—lung cancer	0.015	0.029	CbGbCtD
Linagliptin—CYP3A4—Erlotinib—lung cancer	0.0145	0.028	CbGbCtD
Linagliptin—CYP3A4—Paclitaxel—lung cancer	0.0133	0.0256	CbGbCtD
Linagliptin—CYP3A4—Irinotecan—lung cancer	0.0131	0.0253	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—lung cancer	0.0119	0.023	CbGbCtD
Linagliptin—CYP3A4—Vinblastine—lung cancer	0.0116	0.0225	CbGbCtD
Linagliptin—ABCB1—Methotrexate—lung cancer	0.0116	0.0223	CbGbCtD
Linagliptin—CYP3A4—Etoposide—lung cancer	0.0105	0.0202	CbGbCtD
Linagliptin—CYP3A4—Docetaxel—lung cancer	0.00958	0.0185	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—lung cancer	0.00714	0.0138	CbGbCtD
Linagliptin—Hypersensitivity—Gefitinib—lung cancer	0.000545	0.00423	CcSEcCtD
Linagliptin—Pancreatitis—Irinotecan—lung cancer	0.000544	0.00422	CcSEcCtD
Linagliptin—Malnutrition—Erlotinib—lung cancer	0.000542	0.00421	CcSEcCtD
Linagliptin—Hypoglycaemia—Paclitaxel—lung cancer	0.000536	0.00416	CcSEcCtD
Linagliptin—Back pain—Topotecan—lung cancer	0.00053	0.00411	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—lung cancer	0.000529	0.00411	CcSEcCtD
Linagliptin—Back pain—Erlotinib—lung cancer	0.000524	0.00407	CcSEcCtD
Linagliptin—Pain in extremity—Paclitaxel—lung cancer	0.000523	0.00406	CcSEcCtD
Linagliptin—Nasopharyngitis—Cisplatin—lung cancer	0.000521	0.00405	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Irinotecan—lung cancer	0.000515	0.004	CcSEcCtD
Linagliptin—Rash—Crizotinib—lung cancer	0.000514	0.00399	CcSEcCtD
Linagliptin—Dermatitis—Crizotinib—lung cancer	0.000513	0.00399	CcSEcCtD
Linagliptin—Diarrhoea—Pemetrexed—lung cancer	0.000509	0.00396	CcSEcCtD
Linagliptin—Diarrhoea—Gefitinib—lung cancer	0.000506	0.00393	CcSEcCtD
Linagliptin—Angioedema—Topotecan—lung cancer	0.0005	0.00389	CcSEcCtD
Linagliptin—Pancreatitis—Cisplatin—lung cancer	0.000494	0.00383	CcSEcCtD
Linagliptin—Immune system disorder—Vinorelbine—lung cancer	0.000486	0.00377	CcSEcCtD
Linagliptin—Mediastinal disorder—Vinorelbine—lung cancer	0.000485	0.00377	CcSEcCtD
Linagliptin—Urticaria—Teniposide—lung cancer	0.000479	0.00372	CcSEcCtD
Linagliptin—Cough—Topotecan—lung cancer	0.000478	0.00371	CcSEcCtD
Linagliptin—Cough—Erlotinib—lung cancer	0.000473	0.00367	CcSEcCtD
Linagliptin—Rash—Pemetrexed—lung cancer	0.000469	0.00365	CcSEcCtD
Linagliptin—Dermatitis—Pemetrexed—lung cancer	0.000469	0.00364	CcSEcCtD
Linagliptin—Malnutrition—Vinorelbine—lung cancer	0.000468	0.00364	CcSEcCtD
Linagliptin—Nasopharyngitis—Paclitaxel—lung cancer	0.000468	0.00363	CcSEcCtD
Linagliptin—Rash—Gefitinib—lung cancer	0.000466	0.00362	CcSEcCtD
Linagliptin—Arthralgia—Topotecan—lung cancer	0.000466	0.00362	CcSEcCtD
Linagliptin—Myalgia—Topotecan—lung cancer	0.000466	0.00362	CcSEcCtD
Linagliptin—Dermatitis—Gefitinib—lung cancer	0.000466	0.00362	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.000463	0.0036	CcSEcCtD
Linagliptin—Arthralgia—Erlotinib—lung cancer	0.000461	0.00358	CcSEcCtD
Linagliptin—Myalgia—Erlotinib—lung cancer	0.000461	0.00358	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.000458	0.00356	CcSEcCtD
Linagliptin—Back pain—Vinorelbine—lung cancer	0.000453	0.00352	CcSEcCtD
Linagliptin—Anaphylactic shock—Topotecan—lung cancer	0.000447	0.00347	CcSEcCtD
Linagliptin—Hypersensitivity—Teniposide—lung cancer	0.000444	0.00345	CcSEcCtD
Linagliptin—Infection—Topotecan—lung cancer	0.000444	0.00345	CcSEcCtD
Linagliptin—Pain in extremity—Docetaxel—lung cancer	0.000443	0.00344	CcSEcCtD
Linagliptin—Pancreatitis—Paclitaxel—lung cancer	0.000443	0.00344	CcSEcCtD
Linagliptin—Infection—Erlotinib—lung cancer	0.000439	0.00341	CcSEcCtD
Linagliptin—Skin disorder—Topotecan—lung cancer	0.000434	0.00337	CcSEcCtD
Linagliptin—Skin disorder—Erlotinib—lung cancer	0.00043	0.00334	CcSEcCtD
Linagliptin—Angioedema—Vinorelbine—lung cancer	0.000428	0.00332	CcSEcCtD
Linagliptin—Skin exfoliation—Methotrexate—lung cancer	0.00042	0.00326	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Paclitaxel—lung cancer	0.00042	0.00326	CcSEcCtD
Linagliptin—Diarrhoea—Teniposide—lung cancer	0.000413	0.0032	CcSEcCtD
Linagliptin—Weight increased—Paclitaxel—lung cancer	0.000412	0.0032	CcSEcCtD
Linagliptin—Infestation NOS—Etoposide—lung cancer	0.000411	0.00319	CcSEcCtD
Linagliptin—Infestation—Etoposide—lung cancer	0.000411	0.00319	CcSEcCtD
Linagliptin—Cough—Vinorelbine—lung cancer	0.000409	0.00317	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Topotecan—lung cancer	0.000407	0.00316	CcSEcCtD
Linagliptin—Infestation NOS—Paclitaxel—lung cancer	0.000403	0.00313	CcSEcCtD
Linagliptin—Infestation—Paclitaxel—lung cancer	0.000403	0.00313	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Erlotinib—lung cancer	0.000403	0.00313	CcSEcCtD
Linagliptin—Immune system disorder—Irinotecan—lung cancer	0.000401	0.00311	CcSEcCtD
Linagliptin—Mediastinal disorder—Irinotecan—lung cancer	0.0004	0.00311	CcSEcCtD
Linagliptin—Myalgia—Vinorelbine—lung cancer	0.000399	0.0031	CcSEcCtD
Linagliptin—Arthralgia—Vinorelbine—lung cancer	0.000399	0.0031	CcSEcCtD
Linagliptin—Nasopharyngitis—Docetaxel—lung cancer	0.000397	0.00308	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.000396	0.00308	CcSEcCtD
Linagliptin—Constipation—Vinblastine—lung cancer	0.000393	0.00306	CcSEcCtD
Linagliptin—Urinary tract infection—Paclitaxel—lung cancer	0.000392	0.00304	CcSEcCtD
Linagliptin—Immune system disorder—Gemcitabine—lung cancer	0.000391	0.00303	CcSEcCtD
Linagliptin—Mediastinal disorder—Gemcitabine—lung cancer	0.00039	0.00303	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Topotecan—lung cancer	0.000386	0.003	CcSEcCtD
Linagliptin—Anaphylactic shock—Vinorelbine—lung cancer	0.000382	0.00297	CcSEcCtD
Linagliptin—Constipation—Topotecan—lung cancer	0.000382	0.00297	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Erlotinib—lung cancer	0.000382	0.00296	CcSEcCtD
Linagliptin—Rash—Teniposide—lung cancer	0.00038	0.00295	CcSEcCtD
Linagliptin—Dermatitis—Teniposide—lung cancer	0.00038	0.00295	CcSEcCtD
Linagliptin—Infection—Vinorelbine—lung cancer	0.00038	0.00295	CcSEcCtD
Linagliptin—Constipation—Erlotinib—lung cancer	0.000378	0.00294	CcSEcCtD
Linagliptin—Headache—Teniposide—lung cancer	0.000378	0.00293	CcSEcCtD
Linagliptin—Back pain—Irinotecan—lung cancer	0.000374	0.0029	CcSEcCtD
Linagliptin—Skin disorder—Vinorelbine—lung cancer	0.000371	0.00288	CcSEcCtD
Linagliptin—Diabetes mellitus—Methotrexate—lung cancer	0.000367	0.00285	CcSEcCtD
Linagliptin—Back pain—Gemcitabine—lung cancer	0.000364	0.00283	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—lung cancer	0.000364	0.00283	CcSEcCtD
Linagliptin—Immune system disorder—Cisplatin—lung cancer	0.000364	0.00283	CcSEcCtD
Linagliptin—Mediastinal disorder—Cisplatin—lung cancer	0.000363	0.00282	CcSEcCtD
Linagliptin—Urticaria—Topotecan—lung cancer	0.000355	0.00276	CcSEcCtD
Linagliptin—Malnutrition—Cisplatin—lung cancer	0.000351	0.00272	CcSEcCtD
Linagliptin—Weight increased—Docetaxel—lung cancer	0.000349	0.00271	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Vinorelbine—lung cancer	0.000348	0.00271	CcSEcCtD
Linagliptin—Infestation NOS—Docetaxel—lung cancer	0.000342	0.00265	CcSEcCtD
Linagliptin—Infestation—Docetaxel—lung cancer	0.000342	0.00265	CcSEcCtD
Linagliptin—Hypersensitivity—Vinblastine—lung cancer	0.000339	0.00263	CcSEcCtD
Linagliptin—Cough—Irinotecan—lung cancer	0.000337	0.00262	CcSEcCtD
Linagliptin—Immune system disorder—Etoposide—lung cancer	0.000333	0.00259	CcSEcCtD
Linagliptin—Mediastinal disorder—Etoposide—lung cancer	0.000333	0.00258	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00033	0.00256	CcSEcCtD
Linagliptin—Hypersensitivity—Topotecan—lung cancer	0.000329	0.00256	CcSEcCtD
Linagliptin—Cough—Gemcitabine—lung cancer	0.000328	0.00255	CcSEcCtD
Linagliptin—Constipation—Vinorelbine—lung cancer	0.000327	0.00254	CcSEcCtD
Linagliptin—Immune system disorder—Paclitaxel—lung cancer	0.000327	0.00254	CcSEcCtD
Linagliptin—Mediastinal disorder—Paclitaxel—lung cancer	0.000326	0.00253	CcSEcCtD
Linagliptin—Myalgia—Gemcitabine—lung cancer	0.00032	0.00249	CcSEcCtD
Linagliptin—Arthralgia—Gemcitabine—lung cancer	0.00032	0.00249	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—lung cancer	0.000318	0.00247	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000318	0.00247	CcSEcCtD
Linagliptin—Anaphylactic shock—Irinotecan—lung cancer	0.000315	0.00245	CcSEcCtD
Linagliptin—Malnutrition—Paclitaxel—lung cancer	0.000315	0.00245	CcSEcCtD
Linagliptin—Diarrhoea—Vinblastine—lung cancer	0.000315	0.00244	CcSEcCtD
Linagliptin—Infection—Irinotecan—lung cancer	0.000313	0.00243	CcSEcCtD
Linagliptin—Back pain—Etoposide—lung cancer	0.000311	0.00241	CcSEcCtD
Linagliptin—Anaphylactic shock—Gemcitabine—lung cancer	0.000307	0.00239	CcSEcCtD
Linagliptin—Diarrhoea—Topotecan—lung cancer	0.000306	0.00237	CcSEcCtD
Linagliptin—Infection—Gemcitabine—lung cancer	0.000305	0.00237	CcSEcCtD
Linagliptin—Back pain—Paclitaxel—lung cancer	0.000305	0.00237	CcSEcCtD
Linagliptin—Urticaria—Vinorelbine—lung cancer	0.000304	0.00236	CcSEcCtD
Linagliptin—Diarrhoea—Erlotinib—lung cancer	0.000303	0.00235	CcSEcCtD
Linagliptin—Myalgia—Cisplatin—lung cancer	0.000299	0.00232	CcSEcCtD
Linagliptin—Skin disorder—Gemcitabine—lung cancer	0.000298	0.00232	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000297	0.0023	CcSEcCtD
Linagliptin—Headache—Vinblastine—lung cancer	0.000288	0.00224	CcSEcCtD
Linagliptin—Angioedema—Paclitaxel—lung cancer	0.000288	0.00224	CcSEcCtD
Linagliptin—Anaphylactic shock—Cisplatin—lung cancer	0.000286	0.00222	CcSEcCtD
Linagliptin—Infection—Cisplatin—lung cancer	0.000284	0.00221	CcSEcCtD
Linagliptin—Hypoglycaemia—Doxorubicin—lung cancer	0.000284	0.0022	CcSEcCtD
Linagliptin—Rash—Topotecan—lung cancer	0.000282	0.00219	CcSEcCtD
Linagliptin—Hypersensitivity—Vinorelbine—lung cancer	0.000282	0.00219	CcSEcCtD
Linagliptin—Dermatitis—Topotecan—lung cancer	0.000282	0.00219	CcSEcCtD
Linagliptin—Cough—Etoposide—lung cancer	0.00028	0.00218	CcSEcCtD
Linagliptin—Headache—Topotecan—lung cancer	0.00028	0.00217	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.00028	0.00217	CcSEcCtD
Linagliptin—Rash—Erlotinib—lung cancer	0.000279	0.00217	CcSEcCtD
Linagliptin—Dermatitis—Erlotinib—lung cancer	0.000279	0.00216	CcSEcCtD
Linagliptin—Skin disorder—Cisplatin—lung cancer	0.000278	0.00216	CcSEcCtD
Linagliptin—Immune system disorder—Docetaxel—lung cancer	0.000277	0.00215	CcSEcCtD
Linagliptin—Headache—Erlotinib—lung cancer	0.000277	0.00215	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—lung cancer	0.000277	0.00215	CcSEcCtD
Linagliptin—Mediastinal disorder—Docetaxel—lung cancer	0.000277	0.00215	CcSEcCtD
Linagliptin—Cough—Paclitaxel—lung cancer	0.000275	0.00214	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Irinotecan—lung cancer	0.000272	0.00211	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000272	0.00211	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—lung cancer	0.000271	0.0021	CcSEcCtD
Linagliptin—Constipation—Irinotecan—lung cancer	0.00027	0.00209	CcSEcCtD
Linagliptin—Arthralgia—Paclitaxel—lung cancer	0.000268	0.00208	CcSEcCtD
Linagliptin—Myalgia—Paclitaxel—lung cancer	0.000268	0.00208	CcSEcCtD
Linagliptin—Malnutrition—Docetaxel—lung cancer	0.000267	0.00207	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000266	0.00207	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000265	0.00206	CcSEcCtD
Linagliptin—Constipation—Gemcitabine—lung cancer	0.000263	0.00204	CcSEcCtD
Linagliptin—Anaphylactic shock—Etoposide—lung cancer	0.000262	0.00204	CcSEcCtD
Linagliptin—Diarrhoea—Vinorelbine—lung cancer	0.000262	0.00203	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000261	0.00203	CcSEcCtD
Linagliptin—Infection—Etoposide—lung cancer	0.000261	0.00202	CcSEcCtD
Linagliptin—Back pain—Docetaxel—lung cancer	0.000258	0.00201	CcSEcCtD
Linagliptin—Anaphylactic shock—Paclitaxel—lung cancer	0.000257	0.002	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—lung cancer	0.000257	0.00199	CcSEcCtD
Linagliptin—Infection—Paclitaxel—lung cancer	0.000255	0.00198	CcSEcCtD
Linagliptin—Skin disorder—Etoposide—lung cancer	0.000255	0.00198	CcSEcCtD
Linagliptin—Skin disorder—Paclitaxel—lung cancer	0.00025	0.00194	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—lung cancer	0.000248	0.00192	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Cisplatin—lung cancer	0.000247	0.00192	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—lung cancer	0.000246	0.00191	CcSEcCtD
Linagliptin—Infestation—Methotrexate—lung cancer	0.000246	0.00191	CcSEcCtD
Linagliptin—Rash—Vinorelbine—lung cancer	0.000241	0.00187	CcSEcCtD
Linagliptin—Dermatitis—Vinorelbine—lung cancer	0.000241	0.00187	CcSEcCtD
Linagliptin—Headache—Vinorelbine—lung cancer	0.00024	0.00186	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—lung cancer	0.000235	0.00182	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000234	0.00182	CcSEcCtD
Linagliptin—Cough—Docetaxel—lung cancer	0.000233	0.00181	CcSEcCtD
Linagliptin—Hypersensitivity—Irinotecan—lung cancer	0.000232	0.0018	CcSEcCtD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABCG2—lung cancer	0.000228	0.00533	CbGpPWpGaD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—lung cancer	0.000228	0.00532	CbGpPWpGaD
Linagliptin—Myalgia—Docetaxel—lung cancer	0.000227	0.00177	CcSEcCtD
Linagliptin—Arthralgia—Docetaxel—lung cancer	0.000227	0.00177	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Etoposide—lung cancer	0.000226	0.00176	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—B4GALT5—lung cancer	0.000226	0.00527	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—ADAMTS1—lung cancer	0.000226	0.00527	CbGpPWpGaD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000226	0.00175	CcSEcCtD
Linagliptin—Constipation—Etoposide—lung cancer	0.000224	0.00174	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000222	0.00173	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000222	0.00172	CcSEcCtD
Linagliptin—CYP3A4—Tamoxifen metabolism—CYP2E1—lung cancer	0.000221	0.00517	CbGpPWpGaD
Linagliptin—Constipation—Paclitaxel—lung cancer	0.00022	0.00171	CcSEcCtD
Linagliptin—Anaphylactic shock—Docetaxel—lung cancer	0.000218	0.00169	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—lung cancer	0.000218	0.00169	CcSEcCtD
Linagliptin—Infection—Docetaxel—lung cancer	0.000217	0.00168	CcSEcCtD
Linagliptin—Diarrhoea—Irinotecan—lung cancer	0.000216	0.00168	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—lung cancer	0.000213	0.00166	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—lung cancer	0.000213	0.00166	CcSEcCtD
Linagliptin—Skin disorder—Docetaxel—lung cancer	0.000212	0.00164	CcSEcCtD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—lung cancer	0.000211	0.00493	CbGpPWpGaD
Linagliptin—Hypersensitivity—Cisplatin—lung cancer	0.000211	0.00164	CcSEcCtD
Linagliptin—Diarrhoea—Gemcitabine—lung cancer	0.00021	0.00163	CcSEcCtD
Linagliptin—Urticaria—Etoposide—lung cancer	0.000208	0.00162	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—lung cancer	0.000207	0.00161	CcSEcCtD
Linagliptin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—lung cancer	0.000205	0.00478	CbGpPWpGaD
Linagliptin—Urticaria—Paclitaxel—lung cancer	0.000204	0.00159	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—lung cancer	0.0002	0.00155	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—lung cancer	0.000199	0.00155	CcSEcCtD
Linagliptin—Rash—Irinotecan—lung cancer	0.000199	0.00154	CcSEcCtD
Linagliptin—Dermatitis—Irinotecan—lung cancer	0.000199	0.00154	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000199	0.00154	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—GRP—lung cancer	0.000198	0.00462	CbGpPWpGaD
Linagliptin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—lung cancer	0.000198	0.00462	CbGpPWpGaD
Linagliptin—Headache—Irinotecan—lung cancer	0.000198	0.00153	CcSEcCtD
Linagliptin—Diarrhoea—Cisplatin—lung cancer	0.000196	0.00152	CcSEcCtD
Linagliptin—Rash—Gemcitabine—lung cancer	0.000194	0.0015	CcSEcCtD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—lung cancer	0.000194	0.00452	CbGpPWpGaD
Linagliptin—Dermatitis—Gemcitabine—lung cancer	0.000193	0.0015	CcSEcCtD
Linagliptin—Hypersensitivity—Etoposide—lung cancer	0.000193	0.0015	CcSEcCtD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—lung cancer	0.000193	0.00451	CbGpPWpGaD
Linagliptin—Malnutrition—Methotrexate—lung cancer	0.000192	0.00149	CcSEcCtD
Linagliptin—Headache—Gemcitabine—lung cancer	0.000192	0.00149	CcSEcCtD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—lung cancer	0.000191	0.00446	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—ALDOA—lung cancer	0.00019	0.00444	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—GSTM1—lung cancer	0.00019	0.00443	CbGpPWpGaD
Linagliptin—Hypersensitivity—Paclitaxel—lung cancer	0.000189	0.00147	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Docetaxel—lung cancer	0.000188	0.00146	CcSEcCtD
Linagliptin—Constipation—Docetaxel—lung cancer	0.000186	0.00145	CcSEcCtD
Linagliptin—Back pain—Methotrexate—lung cancer	0.000186	0.00145	CcSEcCtD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—lung cancer	0.000186	0.00434	CbGpPWpGaD
Linagliptin—Rash—Cisplatin—lung cancer	0.000181	0.0014	CcSEcCtD
Linagliptin—Dermatitis—Cisplatin—lung cancer	0.00018	0.0014	CcSEcCtD
Linagliptin—CYP3A4—Estrogen metabolism—CYP1A1—lung cancer	0.00018	0.0042	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—ABCG2—lung cancer	0.00018	0.0042	CbGpPWpGaD
Linagliptin—Diarrhoea—Etoposide—lung cancer	0.000179	0.00139	CcSEcCtD
Linagliptin—Diarrhoea—Paclitaxel—lung cancer	0.000176	0.00137	CcSEcCtD
Linagliptin—Immune system disorder—Doxorubicin—lung cancer	0.000173	0.00134	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—lung cancer	0.000173	0.00134	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—ATF3—lung cancer	0.000172	0.00403	CbGpPWpGaD
Linagliptin—CYP3A4—Irinotecan Pathway—APC—lung cancer	0.000172	0.00402	CbGpPWpGaD
Linagliptin—Cough—Methotrexate—lung cancer	0.000168	0.0013	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—TF—lung cancer	0.000167	0.0039	CbGpPWpGaD
Linagliptin—Malnutrition—Doxorubicin—lung cancer	0.000167	0.00129	CcSEcCtD
Linagliptin—CYP3A4—Xenobiotics—CYP1A1—lung cancer	0.000165	0.00386	CbGpPWpGaD
Linagliptin—Rash—Etoposide—lung cancer	0.000165	0.00128	CcSEcCtD
Linagliptin—Dermatitis—Etoposide—lung cancer	0.000165	0.00128	CcSEcCtD
Linagliptin—Headache—Etoposide—lung cancer	0.000164	0.00128	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—lung cancer	0.000164	0.00127	CcSEcCtD
Linagliptin—Arthralgia—Methotrexate—lung cancer	0.000164	0.00127	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000163	0.00126	CcSEcCtD
Linagliptin—Rash—Paclitaxel—lung cancer	0.000162	0.00126	CcSEcCtD
Linagliptin—Dermatitis—Paclitaxel—lung cancer	0.000162	0.00126	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—lung cancer	0.000161	0.00125	CcSEcCtD
Linagliptin—Headache—Paclitaxel—lung cancer	0.000161	0.00125	CcSEcCtD
Linagliptin—Hypersensitivity—Docetaxel—lung cancer	0.000161	0.00125	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—ENO1—lung cancer	0.00016	0.00374	CbGpPWpGaD
Linagliptin—CYP3A4—Tamoxifen metabolism—CYP1A1—lung cancer	0.000159	0.00371	CbGpPWpGaD
Linagliptin—Anaphylactic shock—Methotrexate—lung cancer	0.000157	0.00122	CcSEcCtD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FOXO3—lung cancer	0.000157	0.00366	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—lung cancer	0.000157	0.00366	CbGpPWpGaD
Linagliptin—Infection—Methotrexate—lung cancer	0.000156	0.00121	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—LMNA—lung cancer	0.000155	0.00361	CbGpPWpGaD
Linagliptin—Skin disorder—Methotrexate—lung cancer	0.000153	0.00119	CcSEcCtD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—lung cancer	0.000151	0.00351	CbGpPWpGaD
Linagliptin—Diarrhoea—Docetaxel—lung cancer	0.000149	0.00116	CcSEcCtD
Linagliptin—Cough—Doxorubicin—lung cancer	0.000145	0.00113	CcSEcCtD
Linagliptin—ABCB1—ABC-family proteins mediated transport—APOA1—lung cancer	0.000144	0.00336	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000143	0.00111	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—lung cancer	0.000142	0.0011	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—lung cancer	0.000142	0.0011	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000141	0.00109	CcSEcCtD
Linagliptin—Rash—Docetaxel—lung cancer	0.000137	0.00107	CcSEcCtD
Linagliptin—Dermatitis—Docetaxel—lung cancer	0.000137	0.00107	CcSEcCtD
Linagliptin—Headache—Docetaxel—lung cancer	0.000137	0.00106	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—lung cancer	0.000136	0.00106	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—lung cancer	0.000136	0.00105	CcSEcCtD
Linagliptin—Infection—Doxorubicin—lung cancer	0.000135	0.00105	CcSEcCtD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—lung cancer	0.000134	0.00312	CbGpPWpGaD
Linagliptin—Skin disorder—Doxorubicin—lung cancer	0.000132	0.00103	CcSEcCtD
Linagliptin—Urticaria—Methotrexate—lung cancer	0.000125	0.000969	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000124	0.000963	CcSEcCtD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—lung cancer	0.000123	0.00288	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CYP2E1—lung cancer	0.000118	0.00276	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—lung cancer	0.000118	0.00274	CbGpPWpGaD
Linagliptin—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000117	0.000912	CcSEcCtD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RHEB—lung cancer	0.000117	0.00273	CbGpPWpGaD
Linagliptin—Constipation—Doxorubicin—lung cancer	0.000116	0.000903	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—lung cancer	0.000116	0.000899	CcSEcCtD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—lung cancer	0.000112	0.00262	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—lung cancer	0.000111	0.00259	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—lung cancer	0.000111	0.00259	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—NODAL—lung cancer	0.000111	0.00259	CbGpPWpGaD
Linagliptin—Urticaria—Doxorubicin—lung cancer	0.000108	0.000839	CcSEcCtD
Linagliptin—Diarrhoea—Methotrexate—lung cancer	0.000107	0.000835	CcSEcCtD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—lung cancer	0.000103	0.0024	CbGpPWpGaD
Linagliptin—Hypersensitivity—Doxorubicin—lung cancer	0.0001	0.000778	CcSEcCtD
Linagliptin—Rash—Methotrexate—lung cancer	9.91e-05	0.000769	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—lung cancer	9.9e-05	0.000769	CcSEcCtD
Linagliptin—Headache—Methotrexate—lung cancer	9.84e-05	0.000764	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—TERT—lung cancer	9.6e-05	0.00224	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—lung cancer	9.56e-05	0.00223	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CAT—lung cancer	9.49e-05	0.00221	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL10—lung cancer	9.44e-05	0.0022	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—lung cancer	9.43e-05	0.0022	CbGpPWpGaD
Linagliptin—Diarrhoea—Doxorubicin—lung cancer	9.31e-05	0.000723	CcSEcCtD
Linagliptin—CYP3A4—Biological oxidations—CNDP2—lung cancer	9.22e-05	0.00215	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM2—lung cancer	9.22e-05	0.00215	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—lung cancer	9.18e-05	0.00214	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—lung cancer	9.12e-05	0.00213	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM2—lung cancer	9.09e-05	0.00212	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—FASLG—lung cancer	8.77e-05	0.00205	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—lung cancer	8.62e-05	0.00201	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP1—lung cancer	8.58e-05	0.002	CbGpPWpGaD
Linagliptin—Rash—Doxorubicin—lung cancer	8.58e-05	0.000666	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—lung cancer	8.57e-05	0.000665	CcSEcCtD
Linagliptin—Headache—Doxorubicin—lung cancer	8.52e-05	0.000662	CcSEcCtD
Linagliptin—CYP3A4—Tryptophan metabolism—CYP1A1—lung cancer	8.5e-05	0.00198	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP2A7—lung cancer	8.34e-05	0.00195	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC34A2—lung cancer	8.25e-05	0.00192	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP2A7—lung cancer	8.22e-05	0.00192	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—lung cancer	7.75e-05	0.00181	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—lung cancer	7.54e-05	0.00176	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—CREBBP—lung cancer	7.5e-05	0.00175	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTA3—lung cancer	7.43e-05	0.00173	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTA3—lung cancer	7.33e-05	0.00171	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—POMC—lung cancer	7.13e-05	0.00166	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—lung cancer	6.87e-05	0.0016	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTA4—lung cancer	6.8e-05	0.00159	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—lung cancer	6.78e-05	0.00158	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—lung cancer	6.72e-05	0.00157	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTA4—lung cancer	6.7e-05	0.00156	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—MMP2—lung cancer	6.64e-05	0.00155	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTA2—lung cancer	6.62e-05	0.00155	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP8—lung cancer	6.53e-05	0.00152	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTA1—lung cancer	6.39e-05	0.00149	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APP—lung cancer	6.37e-05	0.00149	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC22A18—lung cancer	6.25e-05	0.00146	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—AKR1C1—lung cancer	6.03e-05	0.00141	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—lung cancer	6.03e-05	0.00141	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—UGT1A1—lung cancer	5.94e-05	0.00139	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—UGT1A1—lung cancer	5.86e-05	0.00137	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—lung cancer	5.65e-05	0.00132	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—lung cancer	5.57e-05	0.0013	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—JUN—lung cancer	5.54e-05	0.00129	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CXCL8—lung cancer	5.52e-05	0.00129	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—lung cancer	5.48e-05	0.00128	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—MDM2—lung cancer	5.24e-05	0.00122	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CXCL8—lung cancer	5.16e-05	0.0012	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—lung cancer	5.12e-05	0.0012	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—EP300—lung cancer	5.11e-05	0.00119	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—HPGDS—lung cancer	5.05e-05	0.00118	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—CASP3—lung cancer	4.94e-05	0.00115	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL2—lung cancer	4.93e-05	0.00115	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTT1—lung cancer	4.9e-05	0.00114	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GCLC—lung cancer	4.84e-05	0.00113	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP2A6—lung cancer	4.84e-05	0.00113	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—lung cancer	4.84e-05	0.00113	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—lung cancer	4.71e-05	0.0011	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—lung cancer	4.33e-05	0.00101	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—COL4A3BP—lung cancer	4.22e-05	0.000986	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AZIN2—lung cancer	4.22e-05	0.000986	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—lung cancer	4.19e-05	0.000978	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—lung cancer	4.15e-05	0.000969	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP2E1—lung cancer	4.12e-05	0.000961	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP2E1—lung cancer	4.06e-05	0.000948	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—lung cancer	3.99e-05	0.00093	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ABCC3—lung cancer	3.74e-05	0.000874	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ATP5H—lung cancer	3.59e-05	0.000838	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—lung cancer	3.46e-05	0.000807	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—lung cancer	3.42e-05	0.000798	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTP1—lung cancer	3.4e-05	0.000792	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—GNG11—lung cancer	3.39e-05	0.000792	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTP1—lung cancer	3.35e-05	0.000782	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—lung cancer	3.22e-05	0.000752	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—lung cancer	3.21e-05	0.000748	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PLBD1—lung cancer	3.2e-05	0.000747	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—lung cancer	3.12e-05	0.000728	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—AKT1—lung cancer	3.09e-05	0.000721	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	3.08e-05	0.000718	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—lung cancer	3.06e-05	0.000714	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ADCY1—lung cancer	3.05e-05	0.000712	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ABCG2—lung cancer	3.05e-05	0.000712	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1A1—lung cancer	2.96e-05	0.00069	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HSD17B10—lung cancer	2.93e-05	0.000683	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	2.92e-05	0.000681	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—TF—lung cancer	2.84e-05	0.000662	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—lung cancer	2.72e-05	0.000636	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CKB—lung cancer	2.72e-05	0.000635	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—lung cancer	2.71e-05	0.000633	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—lung cancer	2.69e-05	0.000627	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—lung cancer	2.63e-05	0.000613	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AZIN2—lung cancer	2.6e-05	0.000607	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—COL4A3BP—lung cancer	2.6e-05	0.000607	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CNDP2—lung cancer	2.56e-05	0.000597	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM2—lung cancer	2.56e-05	0.000597	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—MTMR3—lung cancer	2.49e-05	0.000581	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—lung cancer	2.44e-05	0.000569	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PGAM1—lung cancer	2.43e-05	0.000566	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—lung cancer	2.37e-05	0.000554	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—lung cancer	2.37e-05	0.000552	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2A7—lung cancer	2.31e-05	0.00054	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—lung cancer	2.29e-05	0.000536	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—lung cancer	2.29e-05	0.000534	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SDC4—lung cancer	2.26e-05	0.000528	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ATP5H—lung cancer	2.21e-05	0.000516	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—POMC—lung cancer	2.21e-05	0.000515	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—lung cancer	2.18e-05	0.00051	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—lung cancer	2.12e-05	0.000496	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—lung cancer	2.07e-05	0.000483	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—RRM1—lung cancer	2.06e-05	0.000481	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA3—lung cancer	2.06e-05	0.000481	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PLBD1—lung cancer	1.97e-05	0.00046	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—AVP—lung cancer	1.97e-05	0.000459	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—lung cancer	1.96e-05	0.000457	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—B4GALT5—lung cancer	1.94e-05	0.000453	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—lung cancer	1.9e-05	0.000444	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA4—lung cancer	1.89e-05	0.00044	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—lung cancer	1.86e-05	0.000434	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA2—lung cancer	1.84e-05	0.000429	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HSD17B10—lung cancer	1.8e-05	0.000421	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTA1—lung cancer	1.77e-05	0.000414	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—lung cancer	1.76e-05	0.00041	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ABCC3—lung cancer	1.75e-05	0.000409	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKR1C1—lung cancer	1.7e-05	0.000396	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CKB—lung cancer	1.68e-05	0.000391	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—UGT1A1—lung cancer	1.65e-05	0.000385	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	1.62e-05	0.000377	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GNG11—lung cancer	1.59e-05	0.000371	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM2—lung cancer	1.58e-05	0.000368	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CNDP2—lung cancer	1.58e-05	0.000368	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	1.56e-05	0.000365	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—MTMR3—lung cancer	1.53e-05	0.000358	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALDOA—lung cancer	1.51e-05	0.000353	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	1.5e-05	0.000351	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PGAM1—lung cancer	1.49e-05	0.000349	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NCOA3—lung cancer	1.47e-05	0.000343	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ABCG2—lung cancer	1.43e-05	0.000334	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ADCY1—lung cancer	1.43e-05	0.000334	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2A7—lung cancer	1.43e-05	0.000333	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—HPGDS—lung cancer	1.4e-05	0.000327	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ENO2—lung cancer	1.4e-05	0.000327	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SDC4—lung cancer	1.4e-05	0.000326	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPP2R1B—lung cancer	1.39e-05	0.000325	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTT1—lung cancer	1.36e-05	0.000317	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GCLC—lung cancer	1.34e-05	0.000314	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2A6—lung cancer	1.34e-05	0.000314	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	1.32e-05	0.000308	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ENO1—lung cancer	1.27e-05	0.000297	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	1.27e-05	0.000297	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—RRM1—lung cancer	1.27e-05	0.000297	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA3—lung cancer	1.27e-05	0.000297	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—B4GALT5—lung cancer	1.19e-05	0.000279	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	1.19e-05	0.000278	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA4—lung cancer	1.16e-05	0.000271	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP2E1—lung cancer	1.14e-05	0.000267	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA2—lung cancer	1.13e-05	0.000264	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—NQO1—lung cancer	1.13e-05	0.000264	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTA1—lung cancer	1.09e-05	0.000255	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCC3—lung cancer	1.08e-05	0.000252	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	1.08e-05	0.000251	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKR1C1—lung cancer	1.05e-05	0.000244	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—STK11—lung cancer	1.02e-05	0.000238	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—UGT1A1—lung cancer	1.02e-05	0.000237	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GNG11—lung cancer	9.79e-06	0.000229	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTP1—lung cancer	9.42e-06	0.00022	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALDOA—lung cancer	9.33e-06	0.000218	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CAT—lung cancer	9.17e-06	0.000214	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NCOA3—lung cancer	9.05e-06	0.000211	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCG2—lung cancer	8.81e-06	0.000206	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ADCY1—lung cancer	8.81e-06	0.000206	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—TYMS—lung cancer	8.76e-06	0.000204	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—lung cancer	8.66e-06	0.000202	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ENO2—lung cancer	8.64e-06	0.000202	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—HPGDS—lung cancer	8.64e-06	0.000202	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPP2R1B—lung cancer	8.58e-06	0.0002	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTT1—lung cancer	8.38e-06	0.000196	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GCLC—lung cancer	8.28e-06	0.000193	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2A6—lung cancer	8.28e-06	0.000193	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1A1—lung cancer	8.21e-06	0.000192	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ERCC2—lung cancer	8.14e-06	0.00019	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ENO1—lung cancer	7.85e-06	0.000183	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—APOA1—lung cancer	7.04e-06	0.000164	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP2E1—lung cancer	7.04e-06	0.000164	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—NQO1—lung cancer	6.96e-06	0.000162	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CG—lung cancer	6.43e-06	0.00015	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—STK11—lung cancer	6.28e-06	0.000146	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—POMC—lung cancer	6.12e-06	0.000143	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CREBBP—lung cancer	5.96e-06	0.000139	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTP1—lung cancer	5.81e-06	0.000136	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CD—lung cancer	5.65e-06	0.000132	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CAT—lung cancer	5.65e-06	0.000132	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALB—lung cancer	5.58e-06	0.00013	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCB1—lung cancer	5.5e-06	0.000128	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—TYMS—lung cancer	5.4e-06	0.000126	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—lung cancer	5.34e-06	0.000125	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1A1—lung cancer	5.06e-06	0.000118	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ERCC2—lung cancer	5.02e-06	0.000117	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CB—lung cancer	4.93e-06	0.000115	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—lung cancer	4.88e-06	0.000114	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—APOA1—lung cancer	4.34e-06	0.000101	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTEN—lung cancer	4.26e-06	9.94e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—EP300—lung cancer	4.06e-06	9.48e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CG—lung cancer	3.96e-06	9.25e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—POMC—lung cancer	3.77e-06	8.8e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CREBBP—lung cancer	3.67e-06	8.57e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CD—lung cancer	3.48e-06	8.13e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALB—lung cancer	3.44e-06	8.02e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CB—lung cancer	3.04e-06	7.09e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—lung cancer	3.01e-06	7.02e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CA—lung cancer	3e-06	7.01e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTEN—lung cancer	2.62e-06	6.12e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—EP300—lung cancer	2.5e-06	5.84e-05	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—AKT1—lung cancer	2.45e-06	5.73e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CA—lung cancer	1.85e-06	4.32e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—AKT1—lung cancer	1.51e-06	3.53e-05	CbGpPWpGaD
